Source: ZIVO Bioscience, Inc.

Health Enhancement Products, Inc. Launches New Website and Toll-Free Phone Service

SCOTTSDALE, AZ--(Marketwire - Jan 25, 2012) - Arizona-based algae producer Health Enhancement Products (OTCBB: HEPI) has launched a new temporary website, signaling its new focus on research-based products for the dietary supplement, food ingredient and medical foods markets. The new URL is -- and the new toll-free phone number is (888) 871-6903. The Michigan local phone number for administration and billing is now (248) 397-4300.

The website is temporary in nature, providing basic information regarding the Company's new direction. A permanent website with additional features will be largely in place within the next 45 days, according to Health Enhancement CEO Andrew Dahl.

Also, due to unanticipated interest in last week's investor conference call, the call-in lines were temporarily overwhelmed and some interested parties where unable to connect. The Company apologizes for the inconvenience and advises those who are interested in hearing the conference call to dial (877) 870-5176 and press 4505436 to access the recording. Access to the recording will be available until end of business, January 31, 2012.

Finally, the Company will be upgrading its corporate identity and updating corporate communications over the next two months.

About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the research and development of natural products derived from algae cultures for use as dietary supplements and food ingredients. These natural products are extracted from living algae grown in purified water.

Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.